Manhattan Scients (MHTX) 0.1350 $MHTX
SeeThruEquity Issues Quarterly Update on Manhattan Scientifics, Highlighting Spencer Falk's Lead Role in MRX Commercialization Efforts
ACCESSWIRE - Wed Aug 27, 8:01AM CDT
New York, NY / ACCESSWIRE / August 27, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Manhattan Scientifics, Inc. (OTCQB: MHTX) for Q2 2014.
Manhattan Scientifics Reaches the Fork (Falk) in the Road
Business Wire - Tue Aug 19, 7:54AM CDT
Spencer Falk, whose marketing expertise was mission-critical to the blockbuster success of Viagra and Celebrex, among other medical brands, today announced that he would lead the commercialization of early cancer detection technology for Senior Scientific, a division of Manhattan Scientifics (OTCQB:MHTX). Mr. Falk previously held senior marketing positions at Pfizer and Forest Laboratories, and has had a 35-year career in the pharmaceutical and diagnostic sector fields.
Manhattan Scientifics Analyst Report; Potentially Disruptive Emerging Technology Play - Monetizing Intellectual Property is the Goal by BrokerBank Securities, Inc.
PR Newswire - Tue Jul 01, 7:30PM CDT
Manhattan Scientifics, Inc. (OTCQB: MHTX) MHTX is an emerging technology incubator/venture firm focused on technology transfer and commercialization of disruptive technologies in the nanomedicine space. The company is presently developing commercial medical prosthetics applications for its ultrafine grain metals and plans to commercialize the cancer research work and nanomedical applications developed by Senior Scientific LLC, a unit of the Company.
SeeThruEquity Issues Company Note on Manhattan Scientifics
ACCESSWIRE - Thu Jun 26, 8:02AM CDT
Company Announces Delivery of MRX II Cancer Detection Instrument to MD Anderson
Manhattan Scientifics Announces Commercial Introduction Of NanoMRX Precision Nanoparticles
Business Wire - Tue Mar 18, 10:45AM CDT
Manhattan Scientifics (OTCQB: MHTX) announced today a collaboration with Azano Biotech that will make NanoMRX Precision Nanoparticles available for purchase.
Manhattan Scientifics (MHTX) Announces Collaboration with MD Anderson Cancer Center to Validate New Instrument for Very Early Detection of Cancer
Business Wire - Mon Jan 27, 10:38AM CST
Manhattan Scientifics (OTC: MHTX) executed an agreement to collaborate with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a breakthrough technology developed by Edward R. Flynn, PhD, for the very early detection of cancer. Dr. Flynn is the founder and chief scientist of MHTX's subsidiary, Senior Scientific LLC. Senior Scientific is seeking to commercialize this patented non-invasive technology using ultra-sensitive magnetic detectors to locate, identify and measure tumors thousands of times smaller than detectable using current technologies.
Manhattan Scientifics engages Loraine Upham to market diagnostic technology
M2 - Mon Aug 26, 5:05AM CDT
Manhattan Scientifics (OTC: MHTX) said that Loraine Upham has been engaged as a consultant to support its cancer team.
Manhattan Scientifics Announces the Engagement of Loraine Upham to Market Its Cancer Diagnostic Technology
Business Wire - Fri Aug 23, 8:00AM CDT
Manhattan Scientifics (OTCQB:MHTX) announced today that Loraine Upham has been engaged as a consultant to support its cancer team. The technology, developed by Edward R. Flynn, PhD, provides the most specific and most sensitive method for detecting cancer currently known. Ms. Upham's role will be to identify initial markets and facilitate relationships with strategic partners for the company.
OTC Daily Alert Stock Watch - Manhattan Scientifics Inc (OTCQB: MHTX)
WorldStockWire - Tue Aug 13, 8:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Senior Scientific Announces Issuance of U.S. Patent for the Detection, Measurement and Imaging of Cancer Cells Using Nanoparticles
Business Wire - Thu May 23, 8:47AM CDT
Senior Scientific, LLC, a unit of Manhattan Scientifics (OTCQB: MHTX) and a developer of molecular imaging and nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the United States Patent Office (USPTO) has issued U.S. Patent No. 8,447,379 entitled "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof."
Manhattan Scientifics Announces Receipt of $2.5M Commitment to Build Breakthrough Cancer Detection Devices Initial $1M Received
Business Wire - Tue Apr 09, 9:46AM CDT
Manhattan Scientifics (MHTX: OTCQB) announced today that it has received the initial $1 million of a $2.5 million commitment to build the first generation of its advanced cancer detection devices. More information can be found in the company's recent 8-K filing.
Cancer Research Breakthrough: The National Foundation for Cancer Research (NFCR) Cites Manhattan Scientifics' Early Cancer Detection Technology as "Research Breakthrough" for 2012
Business Wire - Mon Jan 07, 7:00AM CST
The National Foundation for Cancer Research (NFCR) has listed the SQUID-based cancer imaging technology developed by MHTX's (OTCBB: MHTX) Senior Scientific subsidiary as a "2012 Research Breakthrough." http://nfcr.org/research/research-accomplishments. The technology was developed by Edward R. Flynn, PhD, Senior Scientific's founder and chief scientist, in collaboration with Richard S. Larson, MD, PhD, Executive Vice Chancellor UNM Health Sciences Center in New Mexico.
SeeThruEquity Issues Quarterly Update on Manhattan Scientifics, Highlighting Spencer Falk's Lead Role in MRX Commercialization Efforts
ACCESSWIRE - Wed Aug 27, 8:01AM CDT
New York, NY / ACCESSWIRE / August 27, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Manhattan Scientifics, Inc. (OTCQB: MHTX) for Q2 2014.
Manhattan Scientifics Reaches the Fork (Falk) in the Road
Business Wire - Tue Aug 19, 7:54AM CDT
Spencer Falk, whose marketing expertise was mission-critical to the blockbuster success of Viagra and Celebrex, among other medical brands, today announced that he would lead the commercialization of early cancer detection technology for Senior Scientific, a division of Manhattan Scientifics (OTCQB:MHTX). Mr. Falk previously held senior marketing positions at Pfizer and Forest Laboratories, and has had a 35-year career in the pharmaceutical and diagnostic sector fields.
Manhattan Scientifics Analyst Report; Potentially Disruptive Emerging Technology Play - Monetizing Intellectual Property is the Goal by BrokerBank Securities, Inc.
PR Newswire - Tue Jul 01, 7:30PM CDT
Manhattan Scientifics, Inc. (OTCQB: MHTX) MHTX is an emerging technology incubator/venture firm focused on technology transfer and commercialization of disruptive technologies in the nanomedicine space. The company is presently developing commercial medical prosthetics applications for its ultrafine grain metals and plans to commercialize the cancer research work and nanomedical applications developed by Senior Scientific LLC, a unit of the Company.
SeeThruEquity Issues Company Note on Manhattan Scientifics
ACCESSWIRE - Thu Jun 26, 8:02AM CDT
Company Announces Delivery of MRX II Cancer Detection Instrument to MD Anderson
Manhattan Scientifics Announces Commercial Introduction Of NanoMRX Precision Nanoparticles
Business Wire - Tue Mar 18, 10:45AM CDT
Manhattan Scientifics (OTCQB: MHTX) announced today a collaboration with Azano Biotech that will make NanoMRX Precision Nanoparticles available for purchase.
Manhattan Scientifics (MHTX) Announces Collaboration with MD Anderson Cancer Center to Validate New Instrument for Very Early Detection of Cancer
Business Wire - Mon Jan 27, 10:38AM CST
Manhattan Scientifics (OTC: MHTX) executed an agreement to collaborate with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a breakthrough technology developed by Edward R. Flynn, PhD, for the very early detection of cancer. Dr. Flynn is the founder and chief scientist of MHTX's subsidiary, Senior Scientific LLC. Senior Scientific is seeking to commercialize this patented non-invasive technology using ultra-sensitive magnetic detectors to locate, identify and measure tumors thousands of times smaller than detectable using current technologies.
Manhattan Scientifics engages Loraine Upham to market diagnostic technology
M2 - Mon Aug 26, 5:05AM CDT
Manhattan Scientifics (OTC: MHTX) said that Loraine Upham has been engaged as a consultant to support its cancer team.
Manhattan Scientifics Announces the Engagement of Loraine Upham to Market Its Cancer Diagnostic Technology
Business Wire - Fri Aug 23, 8:00AM CDT
Manhattan Scientifics (OTCQB:MHTX) announced today that Loraine Upham has been engaged as a consultant to support its cancer team. The technology, developed by Edward R. Flynn, PhD, provides the most specific and most sensitive method for detecting cancer currently known. Ms. Upham's role will be to identify initial markets and facilitate relationships with strategic partners for the company.
OTC Daily Alert Stock Watch - Manhattan Scientifics Inc (OTCQB: MHTX)
WorldStockWire - Tue Aug 13, 8:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Senior Scientific Announces Issuance of U.S. Patent for the Detection, Measurement and Imaging of Cancer Cells Using Nanoparticles
Business Wire - Thu May 23, 8:47AM CDT
Senior Scientific, LLC, a unit of Manhattan Scientifics (OTCQB: MHTX) and a developer of molecular imaging and nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the United States Patent Office (USPTO) has issued U.S. Patent No. 8,447,379 entitled "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof."
Manhattan Scientifics Announces Receipt of $2.5M Commitment to Build Breakthrough Cancer Detection Devices Initial $1M Received
Business Wire - Tue Apr 09, 9:46AM CDT
Manhattan Scientifics (MHTX: OTCQB) announced today that it has received the initial $1 million of a $2.5 million commitment to build the first generation of its advanced cancer detection devices. More information can be found in the company's recent 8-K filing.
Cancer Research Breakthrough: The National Foundation for Cancer Research (NFCR) Cites Manhattan Scientifics' Early Cancer Detection Technology as "Research Breakthrough" for 2012
Business Wire - Mon Jan 07, 7:00AM CST
The National Foundation for Cancer Research (NFCR) has listed the SQUID-based cancer imaging technology developed by MHTX's (OTCBB: MHTX) Senior Scientific subsidiary as a "2012 Research Breakthrough." http://nfcr.org/research/research-accomplishments. The technology was developed by Edward R. Flynn, PhD, Senior Scientific's founder and chief scientist, in collaboration with Richard S. Larson, MD, PhD, Executive Vice Chancellor UNM Health Sciences Center in New Mexico.
